Optimi Health Corp., a Health Canada licensed psychedelics pharmaceutical manufacturer, has announced a strategic supply partnership with PsiloThai, a prominent patient advocacy group in Thailand. This agreement is a major milestone as it positions Optimi as the first psychedelics manufacturer to seek approval for its products in the Asian medical market, specifically for use in observational studies on patients dealing with addiction and end-of-life distress.
This development follows a recent regulatory change by Thailand’s Ministry of Public Health, which now permits psilocybin for medical treatment, research, and clinical trials. The directive, effective April 26, 2024, allows the use of psilocybin mushrooms, marking a significant regulatory advancement. Optimi's CEO, Bill Ciprick, expressed excitement about the partnership, highlighting its potential to validate their GMP natural psilocybin extract capsules and advance mental health treatments globally.
The collaboration will facilitate observational studies in conjunction with Government Hospitals and Rajamangala University, targeting patients in hospital care. Optimi and PsiloThai will work together to secure the necessary import certificates to meet supply requirements, with studies commencing upon approval from Thai Health Authorities. This partnership not only enhances research opportunities and expands Optimi's reach into the Asian market but also sets a regulatory precedent that could influence broader acceptance of psychedelics in medical treatments across Asia. Optimi also has a similar agreement with Mind Medicine Australia, further solidifying its global presence in the psychedelics industry.
Click here to read the original news story.